The GSDME gene promoter is hypermethylated

Stable Identifier
R-HSA-9710490
Type
Reaction [omitted]
Species
Homo sapiens
Compartment
nucleoplasm
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
The GSDME gene promoter is hypermethylated
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
5-Methylation of cytosine residues in DNA is a heritable epigenetic mark that regulates gene expression. DNA methyltransferases (DNA MTase, (DNMTs)) catalyze the transfer of the CH3 group from S‑adenosylmethionine (AdoMet) to DNA (Melanie E & Lacey M 2014; Laisne M et al. 2018). DNMTs associate with EZH2 of the Polycomb Repressive Complex 2 (PRC2) (Vire et al. 2006). Aberrant promoter methylation is considered to be a hallmark of cancer (Ehrlich M et al. 2002; Dong Y et al. 2014; Lam K et al. 2016; Croes L et al. 2018). Epigenetic inactivation of GSDME due to hypermethylation of the GSDME promoter region has been linked to tumorigenesis (Akino K et al. 2007; Kim MS et al. 2008a,b; Croes L et al. 2017, 2018; Ibrahim J et al. 2019). Treatment with the DNA methyltransferase inhibitors such as FDA‑approved decitabine (5‑aza‑2'‑deoxycytidine or DAC) may elevate GSDME expression in certain cancer cells (Akino K et al. 2007; Fujikane T et al. 2009; Wang Y et al. 2017).
Literature References
PubMed ID Title Journal Year
28404884 DFNA5 promoter methylation a marker for breast tumorigenesis

de Beeck, KO, Pauwels, P, Croes, L, Van Camp, G, Fransen, E, Vanden Berghe, W, Peeters, M

Oncotarget 2017
18346456 Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer

Yamashita, K, Huang, Y, Chae, YK, Kim, MS, Sidransky, D, Califano, JA, Ratovitski, EA, Nagpal, JK, Trink, B, Chang, X, Lebron, C, Chuang, T

Biochem Biophys Res Commun 2008
18223688 Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma

Sidransky, D, Trink, B, Yamashita, K, Baek, JH, Kim, MS, Nagpal, JK, Wu, G, Chang, X, Mori, M, Ratovitski, EA

Oncogene 2008
30993897 Methylation analysis of Gasdermin E shows great promise as a biomarker for colorectal cancer

Suls, A, Croes, L, Van Camp, G, Fransen, E, Vanden Berghe, W, Beyens, M, Ibrahim, J, Peeters, M, Op de Beeck, K

Cancer Med 2019
Participants
Input
Output
Participates
as an event of
Catalyst Activity

methyltransferase activity of DNMT1,3A,3B:PRC2:Chromatin [nucleoplasm]

Physical Entity
DNMT1,3A,3B:PRC2:Chromatin [nucleoplasm] (Homo sapiens)
Activity
methyltransferase activity (GO:0008168)
This event is regulated
Negatively by
Regulator
Decitabine triphosphate [nucleoplasm]
Active Unit
Decitabine triphosphate [nucleoplasm]
Disease
Name Identifier Synonyms
colon cancer DOID:219
melanoma DOID:1909 Naevocarcinoma, melanoma, melanoma, malignant melanoma, morphology (morphologic abnormality), malignant melanoma NOS (morphologic abnormality), malignant melanoma (disorder), malignant melanoma, malignant melanoma, malignant melanoma, malignant melanoma
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
breast cancer DOID:1612 malignant tumor of the breast, mammary cancer, malignant neoplasm of breast, mammary tumor, primary breast cancer, breast cancer, Ca breast - NOS, breast tumor
Authored
Shamovsky, V  (2020-11-09)
Reviewed
D'Eustachio, P  (2021-02-17)
Kanneganti, TD  (2021-02-17)
Shao, F  (2021-04-22)
Zhang, Z  (2021-02-17)
Created
Shamovsky, V  (2020-12-30)
Cite Us!